| Title |
Mažos molekulinės masės heparinų vaidmuo stabdant vėžinės ligos progresavimą / |
| Translation of Title |
Importance of low molecular mass heparins in stopping the progress of malignancy. |
| Authors |
Morkūnas, Dainius ; Stašinskas, Algimantas ; Narmontas, Deividas |
| DOI |
10.15388/LietChirur.2006.3.2262 |
| Full Text |
|
| Is Part of |
Lietuvos chirurgija.. Vilnius : Vilniaus universiteto leidykla. 2006, t. 4, Nr. 3, p. 192-194.. ISSN 1392-0995. eISSN 1648-9942 |
| Keywords [eng] |
low molecular mass heparin ; thromboembolic disease ; antithrombolic therapy |
| Abstract [eng] |
Low Molecular Mass Heparins (LMMH) are widely used in clinical practice. These anticoagulants are prescribed for the prophylaxis of thromboembolic complications. Recent trials have shown that low molecular mass heparins are effective more in cancer patients with thromboembolism and may lower their mortality. Methods The newest literature on the effectiveness of low molecular mass heparins in the management of thromboembolic disease is reviewed. Multicenter clinical trials are presented. Results By inhibiting the coagulation processes, the LMMH exert a positive effect on tumor growth, invasion, metastasing, and angiogenesis, thus improving the survival. Conclusion Long-lasting 2–4 week antithrombolic LMMH therapy is recommended after major oncologic operations. |
| Published |
Vilnius : Vilniaus universiteto leidykla |
| Type |
Journal article |
| Language |
Lithuanian |
| Publication date |
2006 |
| CC license |
|
